A 31-year-old woman with a history of alcohol pancreatitis presented with abdominal pain. During her initial admission, she developed an 8.2-cm peri-pancreatic fluid collection. She underwent successful endoscopic ultrasound-guided drainage of the collection with a 15 mm lumen-apposing metal stent (LAMS). Though instructed to return, the patient was lost to follow-up. She returned to an outside hospital 7 months later with recurrent pancreatitis secondary to alcohol use. Imaging demonstrated resolution of the peripancreatic collection, with the cyst-gastrostomy stent still in situ. The initial attempt at stent removal was unsuccessful. She was then transferred to our institution.

During endoscopy the LAMS was seen in the gastric body. Endoscopically, it was evident that the plastic covering had been eroded (▶ Video 1). There was visible tissue ingrowth into the LAMS. The gastric flange was detached from the gastric mucosa using a snare. However, the distal flange was imbedded in the tissue. After multiple attempts, the distal flange was successfully removed using rat tooth forceps after detaching it from tissue. The fistula site had mild oozing after stent removal. Examination of the removed stent demonstrated obvious tissue ingrowth through the degraded plastic covering (▶ Fig. 1).

After the development of LAMS, endoscopists have created multiple novel anastomoses between various gastrointestinal lumens. Official recommendation from the manufacturing company is to remove these stents 60 days after deployment. However, various studies have demonstrated outcomes beyond 60 days. Examples include pancreatic fluid collections, benign intestinal tract strictures, gallbladder drainage, choledochoduodenostomy [1–4]. LAMS have remained in place for longer than 2 months, and reportedly have remained patent for greater than 6 months. However, degrading of the plastic coating and tissue ingrowth is a known complication of long-term use of LAMS. Therefore, periodic evaluation of these patients is necessary to ensure timely removal.

Competition interests

Dr. Sharaiha is a consultant for Boston Scientific Corp. and Apollo Endosurgery. Dr. Locke is a Consultant for Boston Scientific Corp. and has received royalty payments from Steris Corp. and Telemed Systems.

The authors

Monica Saumoy, Luai Madanat, David L. Carr-Locke, Reem Z. Sharaiha
Weill Cornell Medicine, New York Presbyterian Hospital, New York, United States

Corresponding author

Reem Z. Sharaiha, MD
Weill Cornell Medicine, New York Presbyterian Hospital, 1305 York Ave, 4th Floor, New York, NY 10021, United States
Fax: +1-646-962-0110
rzs9001@med.cornell.edu
References


Bibliography

DOI: https://doi.org/10.1055/a-0631-7854
Published online: 2018
Endoscopy
© Georg Thieme Verlag KG
Stuttgart - New York
ISSN 0013-726X